Kempkensteffen Carsten, Hinz Stefan, Christoph Frank, Krause Hans, Koellermann Jens, Magheli Ahmed, Schrader Mark, Schostak Martin, Miller Kurt, Weikert Steffen
Department of Urology, Charité, Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Tumour Biol. 2007;28(3):132-8. doi: 10.1159/000103008. Epub 2007 May 21.
Livin has recently been identified as a member of the inhibitor of apoptosis family expressed in several types of cancer but not in most benign tissues. Expression levels of livin were associated with prognosis in various malignancies, but livin expression and its prognostic relevance have not been evaluated in renal cell carcinomas (RCC). In a cohort of 152 RCC patients, we analyzed the relative expression of livin and its splicing variants by real-time RT-PCR and Western blot in tumor and adjacent normal renal tissue specimens. Livin expression was detected in 59 (38.8%) of 152 RCC specimens but in none of the normal samples. Both splicing variants were present in the livin-positive RCC specimens. Livin expression levels did not correlate with pathological or clinical parameters and were not predictive of patient outcome. Our findings suggest that livin expression in RCC is not of prognostic relevance. Further studies to clarify the role of livin expression in RCC and its potential value as a target for immune-mediated tumor destruction are warranted.
Livin最近被确定为凋亡抑制蛋白家族的成员，在多种类型的癌症中表达，但在大多数良性组织中不表达。Livin的表达水平与各种恶性肿瘤的预后相关，但尚未在肾细胞癌（RCC）中评估Livin的表达及其预后相关性。在一组152例RCC患者中，我们通过实时逆转录聚合酶链反应（RT-PCR）和蛋白质免疫印迹法分析了肿瘤及相邻正常肾组织标本中Livin及其剪接变体的相对表达。在152例RCC标本中的59例（38.8%）检测到Livin表达，但在正常样本中均未检测到。两种剪接变体均存在于Livin阳性的RCC标本中。Livin表达水平与病理或临床参数无关，也不能预测患者的预后。我们的研究结果表明，RCC中Livin的表达与预后无关。有必要进一步开展研究以阐明Livin表达在RCC中的作用及其作为免疫介导肿瘤破坏靶点的潜在价值。
